Type B insulin resistance is a rare autoimmune disorder that can lead to a variety of adverse health outcomes. Researchers have recently examined a new treatment option that involves combined immunosuppressive therapy. This regimen includes including rituximab, cyclophosphamide, and high-dose steroid pulses followed by azathioprine maintenance therapy.
The study involved 22 participants with type B insulin resistance. Researchers studied 22 patients with this resistance and found that 86.4% of those who received the combined immunosuppressive therapy achieved remission in five months. This was compared to only about 41% of those who were treated with a single-agent immunosuppressant or plasmapheresis at 30 months. Likewise, no deaths were reported in the combination therapy group compared to 44.8% of those within the single-agent control group.
These findings were published in Diabetes Care on August 10, 2018.